Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rocuronium + sugammadex is a combination used in anesthesia practice. Rocuronium is a non-depolarizing neuromuscular blocking agent (muscle relaxant) that induces temporary paralysis by competitively inhibiting acetylcholine at the neuromuscular junction, facilitating endotracheal intubation and providing skeletal muscle relaxation during surgery or mechanical ventilation. Sugammadex is a modified gamma-cyclodextrin that acts as a selective relaxant binding agent; it rapidly reverses the effects of steroidal non-depolarizing neuromuscular blockers like rocuronium by encapsulating and inactivating them, thereby restoring normal muscle function. This combination allows for rapid onset of paralysis with controlled and predictable reversal, improving safety and efficiency in surgical procedures[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rocuronium + sugammadex.